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BACKGROUND: Long-term predictors and causes of death are understudied in elderly patients with acute
venous thromboembolism.
METHODS:We prospectively followed up 991 patients aged 65 years with acute venous thromboembolism
in a multicenter Swiss cohort study. The primary outcome was overall mortality. We explored the asso-
ciation between patient baseline characteristics and mortality, adjusting for other baseline variables and
periods of anticoagulation as a time-varying covariate. Causes of death over time were adjudicated by a
blinded, independent committee.
RESULTS: The median age was 75 years. During a median follow-up period of 30 months, 206 patients
(21%) died. Independent predictors of overall mortality were age (hazard ratio [HR], 1.32; 95% confidence
interval [CI], 1.05-1.65, per decade), active cancer (HR, 5.80; 95% CI, 4.22-7.97), systolic blood pressure
<100 mm Hg (HR, 2.77; 95% CI, 1.56-4.92), diabetes mellitus (HR, 1.50; 95% CI, 1.02-2.22), low
physical activity level (HR, 1.92; 95% CI, 1.38-2.66), polypharmacy (HR, 1.41; 95% CI, 1.01-1.96),
anemia (HR, 1.48; 95% CI, 1.07-2.05), high-sensitivity C-reactive protein >40 mg/L (HR, 1.88; 95% CI,
1.36-2.60), ultra-sensitive troponin >14 pg/mL (HR, 1.54; 95% CI, 1.06-2.25), and D-dimer >3000 ng/mL
(HR, 1.45; 95% CI, 1.04-2.01). Cancer (34%), pulmonary embolism (18%), infection (17%), and bleeding
(6%) were the most common causes of death.
CONCLUSIONS: Elderly patients with acute venous thromboembolism have a substantial long-term mor-
tality, and several factors, including polypharmacy and a low physical activity level, are associated with study was supported by a grant of the Swiss National 
n (No. 33CSCO-122659/139470).
terest: None.
ll authors had access to the data and played a role in 
cript.
Published in final edited form as: Am J Med. 2017 Feb;130(2):198-206. doi: 10.1016/j.amjmed.2016.09.008long-term mortality. Cancer, pulmonary embolism, infections, and bleeding are the most common causes of 
death in the elderly with venous thromboembolism.
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 Elderly patients with acute venous
thromboembolism have a substantial
long-term overall mortality (21%).
 Besides cancer and arterial hypoten-
sion, predictors of long-term mortality
include polypharmacy and low physical
activity in the elderly with venous
thromboembolism.
 Most elderly patients with venous
thromboembolism die of cancer, pulmo-
nary embolism, infection, and bleeding.The incidence of venous thrombo-
embolism increases sharply with
age, with 27 cases per 100,000
person-years in persons aged 40
years to 410 cases in those aged65
years.1 Patients aged 65 years or
more comprise more than 60% of
venous thromboembolism cases
occurring in the community
setting.2 The elderly not only have a
higher incidence of venous throm-
boembolism but also have an
approximately 2-fold increase in
major bleeding and 2- to 3-fold
greater risk of all-cause mortality
over time than younger patients.2
Despite the higher morbidity and
mortality, venous thromboembo-
lism remains understudied in the elderly,2 and little is known
about the predictors and causes of death in older patients with
venous thromboembolism. Prior studies reporting predictors
and causes of death in elderly patients with venous thrombo-
embolism were limited by a retrospective design,2-4 identified
cases with venous thromboembolism using diagnosis codes
rather than predefined clinical criteria,2 failed to report causes
of death,2,5,6 or determined the cause of deathwithout the use of
a formal adjudication process.4,7-9 Moreover, these studies
almost exclusively focused on short-term mortality (<6
months),3-5,7-9 and predictors and causes of long-term mor-
tality remain largely unknown in the elderly with venous
thromboembolism. To fill these gaps of knowledge, we
aimed to examine which factors drive long-term mortality
and to determine causes of death in a multicenter prospective
study of elderly patients with acute venous thromboembo-
lism using a formal mortality adjudication process.MATERIALS AND METHODS
Cohort Sample
This study was conducted between September 2009 and
December 2013 as part of a prospective multicenter cohort
study that assessed long-term medical outcomes and quality
of life in elderly patients with acute symptomatic venous
thromboembolism from all 5 university and 4 high-volume
nonuniversity hospitals in Switzerland (SWITCO65þ).10
Consecutive patients aged 65 years with an acute,
objectively confirmed venous thromboembolism were
identified in the inpatient and outpatient services of all
participating study sites. We defined symptomatic deep vein
thrombosis as an acute onset of leg pain or swelling plusincomplete compressibility of a
venous segment on ultrasonogra-
phy or an intraluminal filling
defect on contrast venography.11
For iliac and caval deep vein
thrombosis, abnormal duplex flow
patterns compatible with throm-
bosis or an intraluminal filling
defect on computed tomography
or magnetic resonance imaging
venography were used as addi-
tional diagnostic criteria.12-14 Pa-
tients with isolated distal vein
thrombosis were eligible only if
the incompressible distal vein
diameter was at least 5 mm.15,16
We defined symptomatic pulmo-
nary embolism as a positivecomputed tomography or pulmonary angiography, a high-
probability ventilation-perfusion scan, or a proximal deep
vein thrombosis confirmed by compression ultrasonography
or contrast venography in patients with acute chest pain,
new or worsening dyspnea, hemoptysis, or syncope.17,18
Exclusion criteria included inability to provide informed
consent (ie, severe dementia), impossible follow-up (ie,
because of terminal illness), insufficient German or French
speaking ability, thrombosis at a different site than lower
limb, catheter-related thrombosis, or prior enrollment in the
cohort. Ethics committees at each hospital approved the
study, and all patients underwent written informed consent.Baseline Data Collection
Study nurses collected baseline demographics (age, gender),
body mass index, lifestyle factors (smoking status, physical
activity level), comorbidities (diabetes mellitus, arterial hy-
pertension, active cancer, cardiac disease, cerebrovascular
disease, chronic lung disease, chronic liver disease, chronic
renal disease, recent major bleeding, recent major surgery,
immobilization >3 days during the last 3 months, and risk
of falls), vital signs (altered mental status, heart rate, tem-
perature, respiratory rate, systolic blood pressure, and arte-
rial oxygen saturation), laboratory findings (hemoglobin,
creatinine, platelet count, ultra-sensitive troponin, N-termi-
nal pro B-type natriuretic peptide, high-sensitivity C-reac-
tive protein, high-sensitivity D-dimer), and treatments at the
time of diagnosis (concomitant antiplatelet therapy, poly-
pharmacy, anticoagulation before index venous thrombo-
embolism, vitamin K antagonist therapy, and type of initial
parenteral anticoagulation) using standardized data collec-
tion forms. The risk of falls was assessed using 2 validated
Published in final edited form as: Am J Med. 2017 Feb;130(2):198-206. doi: 10.1016/j.amjmed.2016.09.008screening questions: 1) Did you fall during the last year? 2)
Did you notice any problem with gait, balance, or
mobility?19 Patients who answered yes to at least 1
screening question were considered to be at high risk of
falls. Polypharmacy was defined as the prescription of more
than 4 drugs, including St John’s wort, at the time of the
index venous thromboembolism event.20Study Outcome
The outcome was the time to death from all causes after the
index venous thromboembolism. Follow-up included 1
telephone interview and 2 surveillance face-to-face evalua-
tions during the first year of study participation and then
semiannual contacts, alternating between telephone calls
and face-to-face evaluations (clinic visits or home visits in
housebound patients), as well as periodic reviews of the
patients’ hospital chart.10 When death occurred, supple-
mental information was obtained by reviewing medical
charts and interviewing patients’ primary care physicians or
family members. Moreover, nurses obtained information
about the cause of death from hospital discharge letters and
autopsy reports if available. A committee of 3 independent,
blinded clinical experts classified the cause of death as
definitely due to pulmonary embolism, possibly due to
pulmonary embolism, due to major bleeding, or due to
another cause.10 Death was judged to be a definite, fatal
pulmonary embolism if it was confirmed by autopsy or if
death followed a clinically severe pulmonary embolism,
either initially or after an objectively confirmed recurrent
event. Death in a patient who died suddenly without obvious
cause was classified as a possible, fatal pulmonary embo-
lism. Death was judged to be bleeding related if it followed
an intracranial hemorrhage or a bleeding episode leading to
hemodynamic deterioration.21 Final classifications were
made on the basis of the full consensus of this committee.Statistical Analysis
We compared baseline characteristics of patients who died and
those who survived using the chi-square test and the
nonparametric Wilcoxon rank-sum test as appropriate. Mor-
tality rates were calculated for 3 periods of follow-up: 0 to 3
months, 3 to 12 months, and 12 to 36 months. Cumulative
incidences and hazards of death were estimated from a flexible
parametric survival model using 2 degrees of freedom for the
baseline hazard function and time-constant covariates.22 Time
dependence of covariates and adequate number of degrees of
freedom were explored using model comparisons.
We explored associations between patient baseline
characteristics and overall mortality using Cox regression
analysis, adjusting for other baseline variables and periods
of anticoagulation as a time-varying covariate. Missing
values were imputed using chained equations. Imputation
models were based on all other variables, as well as an in-
dicator variable for death and the duration of follow-up. In
total, 20 imputed data sets were generated, which wereanalyzed as described earlier using Rubin’s rules to combine
results across data sets.23 In a sensitivity analysis, all
missing values were assumed to be normal. We also
compared causes of death across time periods (0-3 months,
3-12 months, and >12 months). All analyses were per-
formed using Stata 14 (StataCorp LP, College Station, Tex).RESULTS
Study Sample
Of the 1003 patients initially enrolled in the cohort,10 8 pa-
tients refused the use of their data and 4 withdrew from the
study within 1 day of enrollment, leaving a final study sample
of 991 patients. Patients had a median age of 75 years, and
463 (47%) were women (Table 1). Overall, 687 patients
(69%) had pulmonary embolism  deep vein thrombosis,
whereas 304 patients (31%) had deep vein thrombosis
only. Compared with patients with deep vein thrombosis
only, patients with pulmonary embolism  deep vein
thrombosis had a higher body mass index (27 vs 26 kg/m2,
P ¼ .01) and were more likely to have arterial
hypertension (66% vs 60%, P ¼ .049), a heart rate 110
beats/min (12% vs 2%, P <.001), a respiratory rate 30
breaths/min (5% vs 2%, P ¼ .02), an arterial oxygen
saturation <90% (16% vs 3%, P <.001), and elevated
troponin (53% vs 46%, P ¼ .04), N-terminal pro B-type
natriuretic peptide (66% vs 50%, P <.001), and C-reactive
protein levels (40% vs 25%, P <.001), whereas patients
with deep vein thrombosis only were more likely to be
anemic (50% vs 39%, P ¼ .003). Age, arterial
hypotension, active cancer, and other comorbidities did not
differ between patients with pulmonary embolism  deep
vein thrombosis and those with deep vein thrombosis only.
A total of 206 patients (21%) died during a median follow-
up of 30 months (interquartile range, 19-36 months). Patients
who died were older, had a lower body mass index, and were
more likely to have comorbidities, including cancer, diabetes
mellitus, cardiac disease, cerebrovascular disease, and chronic
lung and renal disease, than those who survived (Table 1).
They also more frequently had polypharmacy, a high risk of
falls, and a low physical activity level, whereas recent major
surgery was less common. Patients who died also were more
likely to have arterial hypotension and a low arterial oxygen
saturation on admission, as well as pathologic laboratory
findings, including anemia, thrombocytopenia, and elevated
creatinine, C-reactive protein, troponin, N-terminal pro
B-type natriuretic peptide, and D-dimer levels.Cumulative Incidences of Overall Mortality
Of the 206 patients who died, 53 (26%) died within the first 3
months after the index venous thromboembolism, 60 (29%)
died between month 3 and 12, and 93 (45%) died after 12
months. The mortality incidence was highest during the first 3
months after the index venous thromboembolismanddecreased
over time (Table 2).Most patients diedwithin 12months of the
index venous thromboembolism (Figure A). The cumulative
Table 1 Patient Baseline Characteristics by Survival Status
Characteristic
n (%) or Median (IQR)
P Value
Missing
Values n (%)All (N ¼ 991)
Patients Who
Died (N ¼ 206)
Patients Who
Survived (N ¼ 785)
Patient age (y) 75 (69-81.0) 78 (71-84) 74 (69-80) <.001 0 (0)
Female gender 463 (47) 97 (47) 366 (47) .91 0 (0)
BMI, kg/m2 27 (24-30) 25 (23-28) 27 (25-30) <.001 5 (1)
Current or past smoker 479 (48) 106 (52) 373 (48) .26 3 (0)
PE  DVT 687 (69) 137 (67) 550 (70) .32 0 (0)
DVT only 304 (31) 69 (33) 235 (30) .32 0 (0)
Diabetes mellitus 155 (16) 42 (20) 113 (14) .04 0 (0)
Arterial hypertension 638 (64) 136 (66) 502 (64) .58 0 (0)
Active cancer* 178 (18) 95 (46) 83 (11) <.001 0 (0)
Cardiac disease§ 118 (12) 37 (18) 81 (10) <.01 0 (0)
Cerebrovascular disease¶ 92 (9) 32 (16) 60 (8) <.01 0 (0)
Chronic lung disease† 136 (14) 45 (22) 91 (12) <.001 0 (0)
Chronic liver disease‡ 14 (1) 4 (2) 10 (1) .47 0 (0)
Chronic renal diseasek 185 (19) 52 (25) 133 (17) <.01 0 (0)
Prior VTE 283 (29) 51 (25) 232 (30) .18 0 (0)
Recent major bleeding# 47 (5) 13 (6) 34 (4) .23 0 (0)
Recent major surgery** 149 (15) 21 (10) 128 (16) .03 0 (0)
Immobilization >3 d during the last 3 mo 219 (22) 49 (24) 170 (22) .51 0 (0)
High risk of fall†† 457 (46) 119 (58) 338 (43) <.001 2 (0)
Low physical activity‡‡ 367 (37) 122 (60) 245 (31) <.001 3 (0)
Altered mental status 41 (4) 8 (4) 33 (4) .83 3 (0)
Heart rate 110 beats/min 88 (9) 23 (11) 65 (8) .22 22 (2)
Temperature <36C 70 (8) 17 (9) 53 (7) .45 77 (8)
Respiratory rate 30 breaths/min 33 (4) 10 (6) 23 (4) .23 207 (21)
Systolic BP <100 mm Hg 35 (4) 16 (8) 19 (2) <.001 18 (2)
Arterial oxygen saturation <90% 107 (14) 31 (19) 76 (13) .04 230 (23)
Anemia§§ 388 (42) 123 (62) 265 (36) <.001 63 (6)
Creatinine >1.5 mg/dL 99 (11) 30 (15) 69 (10) .03 79 (8)
Platelet count <150 g/L 140 (15) 42 (21) 98 (13) <.01 63 (6)
us cTnT >14 pg/mL 439 (51) 125 (69) 314 (46) <.001 129 (13)
NT-proBNP >300 pg/mL 525 (61) 143 (79) 382 (56) <.001 129 (13)
hs-CRP >40 mg/L 308 (36) 87 (48) 221 (32) <.001 124 (13)
D-dimer >3000 ng/mL 332 (39) 81 (46) 251 (38) .04 148 (15)
Concomitant antiplatelet therapykk 321 (32) 76 (37) 245 (31) .12 0 (0)
Polypharmacy¶¶ 504 (51) 138 (67) 366 (47) <.001 0 (0)
Anticoagulation before index VTE 51 (5) 14 (7) 37 (5) .23 0 (0)
Parenteral anticoagulation .010
LMWH 465 (47) 89 (43) 376 (48) .23
UFH 333 (34) 83 (40) 250 (32) .02
Fondaparinux 158 (16) 23 (11) 135 (17) .04
Danaparoid 1 (0) 1 (0) 0 (0) -
None 34 (3) 10 (5) 24 (3) .21
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pulmonary embolism  deep vein thrombosis and those with
deep vein thrombosis only (Figure B), whereas patients with
cancer had a substantially higher cumulative incidence of
death than patients without cancer (Figure C).Predictors of Overall Mortality
Active cancer (adjusted hazard ratio [HR], 5.80; 95% con-
fidence interval [CI], 4.22-7.97) was the strongest predictorof overall mortality, followed by arterial hypotension (HR,
2.77; 95% CI, 1.56-4.92) (Table 3). Other predictors of
mortality were age (HR, 1.32; 95% CI, 1.05-1.65, per
decade), diabetes mellitus (HR, 1.50; 95% CI, 1.02-2.22),
a low physical activity level (HR, 1.92; 95% CI, 1.38-
2.66), polypharmacy (HR, 1.41; 95% CI, 1.01-1.96),
anemia (HR, 1.48; 95% CI, 1.07-2.05), C-reactive protein
>40 mg/L (HR, 1.88; 95% CI, 1.36-2.60), troponin >14
pg/mL (HR, 1.54; 95% CI, 1.06-2.25), and D-dimer
>3000 ng/mL (HR, 1.45; 95% CI, 1.04-2.01). Body mass
Table 1 Continued
Characteristic
n (%) or Median (IQR)
P Value
Missing
Values n (%)All (N ¼ 991)
Patients Who
Died (N ¼ 206)
Patients Who
Survived (N ¼ 785)
VKA therapy 861 (87) 129 (63) 732 (93) <.001 0 (0)
Inferior vena cava filter 11 (1) 3 (1) 8 (1) .59 0 (0)
Thrombolysis## 30 (3) 6 (3) 24 (3) .91 0 (0)
BMI ¼ body mass index; BP ¼ blood pressure; DVT ¼ deep venous thrombosis; hs-CRP ¼ high-sensitivity C-reactive protein; IQR ¼ interquartile range;
LMWH ¼ low-molecular-weight heparin; NT-proBNP ¼ N-terminal pro B-type natriuretic peptide; PE ¼ pulmonary embolism; UFH ¼ unfractionated heparin;
us-cTnT ¼ ultra-sensitive cardiac troponin; VKA ¼ vitamin K antagonist; VTE ¼ venous thromboembolism.
*Solid or hematologic cancer requiring chemotherapy, radiotherapy, surgery, or palliative care during the last 3 months.
†Known chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension, or bronchiectasis.
‡Liver cirrhosis, chronic hepatitis, chronic liver failure, or hemochromatosis.
§Acute heart failure during the last 3 months, a known history of systolic or diastolic heart failure, left or right heart failure, forward or backward heart
failure, left ventricular ejection fraction <40%, or a myocardial infarction during the last 3 months.
kDiabetic or hypertensive nephropathy, chronic glomerulonephritis or interstitial nephritis, myeloma-related nephropathy, or cystic kidney disease.
¶History of ischemic or hemorrhagic stroke with hemiparesis, hemiplegia, or paraplegia at the time of screening.
#Any bleeding leading to a hospital admission or red blood cell transfusions during the last 3 months.
**Within 3 months of the index venous thromboembolism.
††Based on self-report (fall during the previous year or any subjective problem with gait, balance, or mobility).
‡‡Based on self-report (“I am mostly sitting or lying, do not move a lot” or “I often walk but I avoid climbing stairs or carrying light weight”).
§§Serum hemoglobin concentration <13 g/dL for men or <12 g/dL for women.
kkUse of aspirin, clopidogrel, prasugrel, or aspirin/dipyridamole.
¶¶Prescription of >4 drugs, including St John’s wort. The intake of vitamins or alternative medicine was not considered.
##Catheter-directed or systemic thrombolysis.
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surgery (HR, 0.34; 95% CI, 0.19-0.59) were inversely
associated with mortality.Table 2 Mortality Rates
Patients (n)
Deaths per 100
Patient-Y (95% CI)
All patients
0-3 mo 991 22.2 (17.0-29.1)
3-12 mo 925 9.2 (7.1-11.8)
12-36 mo 841 6.4 (5.1-7.9)
Patients with PE  DVT
0-3 mo 687 23.7 (17.3-32.5)
3-12 mo 637 10.5 (7.9-14.0)
12-36 mo 575 5.1 (3.8-6.9)
Patients with DVT only
0-3 mo 304 19.0 (11.2-32.0)
3-12 mo 288 6.3 (3.6-10.8)
12-36 mo 266 9.1 (6.6-12.6)
Patients with cancer
0-3 mo 178 81.6 (57.7-115.3)
3-12 mo 142 39.2 (28.1-54.6)
12-36 mo 106 21.0 (14.5-30.3)
Patients without cancer
0-3 mo 813 10.6 (6.9-16.2)
3-12 mo 783 4.4 (3.0-6.5)
12-36 mo 735 4.6 (3.5-6.1)
CI ¼ confidence interval; DVT ¼ deep venous thrombosis;
PE ¼ pulmonary embolism; VTE ¼ venous thromboembolism.A separate analysis showed that mortality predictors
somewhat differed by type of venous thromboembolism
(Table 3). Diabetes, low physical activity, anemia, and
elevated cardiac biomarkers were associated with mortality
only in patients with pulmonary embolism  deep vein
thrombosis, whereas age and polypharmacy were
statistically significant predictors of death only in patients
with isolated deep vein thrombosis.
Overall, we observed relatively few missing values
(Table 1). When missing values were assumed to be normal
in a sensitivity analysis, the results did not change markedly
(data not shown).
Causes of Death
The cause of death could be determined in 185 patients (90%)
(Table 4). Overall, 70 patients (34%) died of cancer, 36
patients (18%) died of definite or possible pulmonary
embolism, 34 patients (17%) died of infection, and 13
patients (6%) died of bleeding complications. Among
patients who died during the first 3 months of the index
venous thromboembolism, the main causes of death were
cancer (38%), definite/possible pulmonary embolism
(26%), and infection (13%). Cancer remained the leading
cause of death during the entire follow-up period. During
the first 12 months, definite/possible pulmonary embolism
and bleeding represented the second and fourth leading causes
of death, respectively. Although definite/possible pulmonary
embolism and bleeding remained important causes of death
during long-term follow-up, the proportion of patients who
died of infections and cardiac diseases increased over time.
Figure Cumulative incidences andhazards of death. (A)Overall cumulative incidence andhazardof
death. The 3-year cumulative incidence of deathwas 21.7%.Dashed lines indicate the upper and lower
boundary of the 95% CI. (B) Cumulative incidences and hazards of death by type of index venous
thromboembolism. The 3-year cumulative incidence of death was 21.3% for patients with pulmonary
embolism deep vein thrombosis and 22.5% for patients with deep vein thrombosis only (P¼ .692
based on a Wald test). Dashed lines indicate the upper and lower boundary of the 95% CI. (C) Cu-
mulative incidences and hazards of death by cancer status. The 3-year cumulative incidence of death
was 60.2% for patients with cancer and 13.4% for patients without cancer (P<.001 based on a Wald
test).Dashed lines indicate theupper and lower boundaryof the95%CI.DVT¼ deepvein thrombosis;
PE¼ pulmonary embolism.
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Table 3 Predictors of Mortality
Predictors
Adjusted* HR (95% CI)
All Patients (n ¼ 991) PE  DVT (n ¼ 687) DVT Only (n ¼ 304)
Age (per decade) 1.32 (1.05-1.65) 1.12 (0.84-1.50) 2.00 (1.27-3.14)
Female gender 0.96 (0.68-1.36) 0.85 (0.56-1.31) 1.29 (0.65-2.55)
BMI >30 kg/m2 0.93 (0.90-0.96) 0.91 (0.87-0.95) 0.89 (0.83-0.95)
Current or past smoker 0.93 (0.66-1.29) 0.87 (0.58-1.31) 1.14 (0.58-2.23)
Diabetes mellitus 1.50 (1.02-2.22) 1.62 (1.02-2.58) 1.61 (0.71-3.66)
Arterial hypertension 0.94 (0.68-1.31) 1.02 (0.66-1.56) 0.63 (0.33-1.20)
Active cancer 5.80 (4.22-7.97) 4.84 (3.25-7.23) 13.44 (6.68-27.06)
Cardiac disease 1.37 (0.92-2.03) 1.44 (0.87-2.37) 1.81 (0.79-4.16)
Cerebrovascular disease 1.29 (0.85-1.96) 1.62 (0.95-2.76) 0.53 (0.22-1.30)
Chronic lung disease 1.26 (0.86-1.85) 1.40 (0.90-2.17) 0.77 (0.25-2.38)
Chronic liver disease 0.77 (0.26-2.22) 1.81 (0.50-6.61) 0.10 (0.01-1.20)
Chronic renal disease 1.05 (0.71-1.54) 1.04 (0.63-1.72) 1.43 (0.67-3.08)
Prior VTE 1.10 (0.78-1.57) 1.19 (0.77-1.84) 0.93 (0.47-1.83)
Recent major bleeding 0.70 (0.36-1.36) 0.73 (0.35-1.53) 0.21 (0.02-2.06)
Recent major surgery 0.34 (0.19-0.59) 0.26 (0.13-0.54) 0.34 (0.13-0.92)
Immobilization during the last 3 mo 0.94 (0.63-1.41) 0.74 (0.46-1.22) 1.53 (0.70-3.35)
Polypharmacy 1.41 (1.01-1.96) 1.31 (0.86-1.98) 2.96 (1.48-5.91)
High risk of fall 1.04 (0.76-1.43) 1.01 (0.68-1.52) 1.23 (0.61-2.49)
Low physical activity 1.92 (1.38-2.66) 2.37 (1.56-3.61) 1.12 (0.58-2.16)
PE as the index event 1.17 (0.84-1.63) NA NA
Altered mental status 0.63 (0.29-1.35) 0.58 (0.21-1.63) 0.44 (0.11-1.82)
Heart rate 110 beats/min 0.91 (0.54-1.53) 0.78 (0.44-1.39) 2.06 (0.30-14.26)
Temperature <36C 1.09 (0.62-1.92) 1.40 (0.73-2.68) 0.65 (0.20-2.14)
Respiratory rate 30 breaths/min 1.69 (0.90-3.20) 1.74 (0.83-3.62) 1.30 (0.20-8.55)
Systolic BP <100 mm Hg 2.77 (1.56-4.92) 2.51 (1.19-5.28) 7.79 (2.04-29.66)
Arterial oxygen saturation <90% 1.26 (0.80-1.99) 1.35 (0.82-2.23) 0.84 (0.12-5.93)
Anemia 1.48 (1.07-2.05) 1.61 (1.09-2.39) 1.37 (0.65-2.93)
Creatinine >1.5 mg/dL 0.86 (0.53-1.39) 0.77 (0.42-1.40) 1.20 (0.42-3.49)
Platelet count <150 g/L 1.28 (0.89-1.85) 1.07 (0.66-1.73) 1.94 (0.93-4.07)
us cTnT >14 pg/mL 1.54 (1.06-2.25) 2.18 (1.32-3.58) 0.60 (0.28-1.27)
NT-proBNP >300 pg/mL 1.35 (0.89-2.06) 1.48 (0.85-2.59) 1.26 (0.56-2.87)
hs-CRP >40 mg/L 1.88 (1.36-2.60) 2.02 (1.35-3.03) 1.50 (0.76-2.97)
D-dimer >3000 ng/mL 1.45 (1.04-2.01) 1.47 (0.97-2.24) 1.39 (0.73-2.65)
BMI ¼ body mass index; BP ¼ blood pressure; CI ¼ confidence interval; DVT ¼ deep venous thrombosis; HR ¼ hazard ratio; hs-CRP ¼ high-sensitivity
C-reactive protein; NA ¼ not applicable; NT-proBNP ¼ N-terminal pro B-type natriuretic peptide; PE ¼ pulmonary embolism; us-cTnT ¼ ultra-sensitive
cardiac troponin; VTE ¼ venous thromboembolism.
*Adjustments were made for all other baseline variables.
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Our results show that elderly patients with acute venous
thromboembolism have a substantial long-term mortality
(21%) and that several clinical factors (age, diabetes, cancer,
polypharmacy, low physical activity, systolic hypotension)
and laboratory abnormalities (anemia and elevated troponin,
C-reactive protein, and D-dimer) are associated with an
increased risk of long-term mortality. Cancer, pulmonary
embolism, infections, and bleeding are the most common
causes of death in the elderly with venous thromboembolism.
Prior retrospective and prospective studies that examined
predictors of 3-year mortality in older patients with venous
thromboembolism found an episode of major bleeding after
the index venous thromboembolism and age 80 years to be
predictors of all-cause mortality.2,6 The remaining studies
examining predictors of death in the elderly with venousthromboembolism focused exclusively on short-term mor-
tality (<6 months) in patients with pulmonary embolism, the
more severe form of venous thromboembolism.3-5,8 These
studies demonstrated that comorbid burden, cancer, cardio-
vascular and neurodegenerative diseases, chronic lung dis-
ease, arterial hypotension, hypoxemia, thrombocytopenia,
and elevated cardiac troponins were associated with all-cause
mortality.3-5,8 Our study extends the existing knowledge by
identifying several additional factors that are associated with
long-term mortality in the elderly with acute venous throm-
boembolism. In addition to age, cancer, arterial hypotension,
and several laboratory abnormalities at the time of admission,
our study also identified polypharmacy and a low level of
physical activity as predictors of long-term mortality in the
elderly with venous thromboembolism. Both polypharmacy
and a low physical activity level were previously shown to be
Table 4 Causes of Death
Cause of Death
n (%)
P ValueAll Deaths (N ¼ 206)
Deaths
0-3 Mo (N ¼ 53)
Deaths
3-12 Mo (N ¼ 60)
Deaths
>12 Mo (N ¼ 93)
Cancer 70 (34) 20 (38) 28 (47) 22 (24) .064
Definite or possible PE 36 (18) 14 (26) 8 (13) 14 (15)
Infection 34 (17) 7 (13) 7 (12) 20 (22)
Bleeding 13 (6) 3 (6) 5 (8) 5 (5)
Left ventricular failure 13 (6) 2 (4) 3 (5) 8 (9)
Pulmonary causes 7 (3) 2 (4) 4 (7) 1 (1)
Acute coronary syndrome 3 (2) 1 (2) 0 (0) 2 (2)
Suicide 3 (2) 0 (0) 0 (0) 3 (3)
Ischemic stroke 2 (1) 0 (0) 0 (0) 2 (2)
Other* 4 (2) 0 (0) 2 (3) 2 (2)
Unknown 21 (10) 4 (8) 3 (5) 14 (15)
PE ¼ pulmonary embolism.
*Trauma (n ¼ 1), renal failure (n ¼ 1), decompensated liver cirrhosis (n ¼ 1), and peripheral artery occlusive disease (n ¼ 1).
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venous thromboembolism, possibly as a consequence of a
higher risk of falls and comorbid burden.24,25 Whether the
reduction of polypharmacy or an increase in physical activity
has the potential to improve survival in the elderly with
venous thromboembolism should be further examined.
Of note, in contrast to a prior study from the 1980s that
demonstrated a higher mortality in elderly patients presenting
with pulmonary embolism compared with deep vein throm-
bosis,26 our results did not show a mortality difference be-
tween patients with pulmonary embolism  deep vein
thrombosis and those with deep vein thrombosis only, despite
the fact that patients with pulmonary embolism  deep vein
thrombosis had more signs of acute physiologic derangement
(tachycardia, tachypnea, hypoxemia) and right ventricular
dysfunction (elevated troponin and N-terminal pro B-type
natriuretic peptide values) at the time of diagnosis. A po-
tential explanation is that short- and long-term prognoses of
elderly patients with venous thromboembolism may be
driven by comorbid diseases than by the severity of the initial
venous thromboembolism event.6 Moreover, as shown in a
Danish cohort study, the 30-day mortality rate ratios for
pulmonary embolism, compared with patients without
venous thromboembolism, declined markedly from 138 in
1980 to 1989 to 36 in 2000 to 2011 for pulmonary embolism,
possibly because of the use of improved diagnostic imaging
with detection of less severe pulmonary embolism and
improvement in the treatment of pulmonary embolism.27
To our knowledge, no prior study examined long-term
causes of death in elderly patients with venous thrombo-
embolism. In our study, cancer was the most common cause
of death over time. Although pulmonary embolism
remained the second leading cause of death during the first
12 months, other causes of death (infections, cardiovascular
causes) became more common after 12 months of follow-
up. The proportion of patients who died of bleeding
remained fairly constant over time (5%-8%).Overall, 26% of patients died of definite or possible
pulmonary embolism during the first 3 months in our cohort.
Our results are consistent with 2 prior studies demonstrating
that the proportion of octogenarians and nonagenarians who
died of pulmonary embolism within 3 months of the index
venous thromboembolism was 27% and 32%, respec-
tively.7,9 Other studies showed that the proportion of older
patients with pulmonary embolism who died of pulmonary
embolism decreased with increasing length of follow-up and
varied from 91% in patients who died in the hospital to 21%
in patients who died within 6 months.3,4,8
In times of declining autopsy rates, cause-of-death ascer-
tainment is challenging in patients with venous thromboem-
bolism. We used a committee of independent and blinded
clinical experts to adjudicate causes of death, with the final
adjudication based on the full consensus of the committee. In
prior studies reporting cause of death in the elderly with
venous thromboembolism, causes of death were assigned by
unblinded attending physicians7,9 or based on death certifi-
cates only,3 or the method of ascertaining cause of death was
not specified.4,8 Evidence suggests significantly exaggerated
treatment effects in clinical trials with nonblinded versus
blinded assessors for binary and scale measurement out-
comes,28,29 and cause-of-death ascertainment based on death
certificates may substantially differ from autopsy findings.30
To reduce the risk of ascertainment bias, the use of adjudi-
cation committees has been advocated and quality criteria for
planning and reporting such committees have been estab-
lished,31 including the type of information provided to the
committee, the blinding/independence of the committee
members, and the method of reaching a final decision.Study Limitations
Our study has potential limitations. First, the cohort used for
this analysis excluded patients with severe dementia or ter-
minal illness,10 which may have led to an underestimation of
Published in final edited form as: Am J Med. 2017 Feb;130(2):198-206. doi: 10.1016/j.amjmed.2016.09.008mortality. Indeed, the Worcester Venous Thromboembolism
Study reported a 3-year mortality of 37% in older patients
compared with 21% in our study.6 Second, our cohort
included patients aged 65 years only, and we could not
compare predictors and causes of death in older versus
younger patients. Finally, we can only detect associations, not
causality, from these data. Thus, we cannot determinewhether
the clinical and laboratory factors associated with mortality
(ie, age, diabetes, cancer, polypharmacy, low physical activ-
ity, anemia, and elevated C-reactive protein) have a specific
effect on the pathophysiology of pulmonary embolism or
whether they are simply markers of adverse outcome.
CONCLUSIONS
Our prospective multicenter cohort study provides new
insight into long-term predictors and causes of death in
elderly patients with venous thromboembolism, an under-
studied clinical area. Several clinical factors that are highly
prevalent among the elderly, including cancer, poly-
pharmacy, and low physical activity, were associated with
an increased risk of long-term mortality. Cancer, pulmonary
embolism, infections, and bleeding were the most common
causes of death.
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